Embecta Corp. (EMBC) Stock Grade

About Embecta Corp.'s fundamentals

Embecta Corp. operates as a specialty and generic drug manufacturer with a market capitalization of $822.7 million and trades at a P/E ratio of 8.6, suggesting a relatively low valuation relative to earnings. The company generated a net margin of 8.8%, indicating it retains roughly 9 cents of profit for every dollar of revenue, though revenue declined 3.8% year-over-year, signaling contraction in its top line. Embecta provides shareholders with a 4.3% dividend yield, which is notable given the company's modest profitability metrics and recent revenue headwinds.